BioCardia (BCDA) Registration Filing summary

Company overview and business model

• Clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases with significant unmet needs.

• Two cell therapy platforms in clinical trials: CardiAMP (autologous) for ischemic heart failure and refractory angina, and CardiALLO (allogeneic) for ischemic heart failure and ARDS.

• Proprietary Helix transendocardial delivery system supports both in-house and partnered biotherapeutic programs.

• Recent regulatory engagement in Japan and positive clinical data in chronic myocardial ischemia trial.

Financial performance and metrics

• History of operating losses and ongoing need for substantial additional financing to achieve business goals.

• Net proceeds from the offering estimated at $5.3 million, with quarterly cash expenditures of approximately $1.6 million as of June 30, 2025.

• As adjusted net tangible book value post-offering would be $0.33 per share, with immediate dilution of $1.94 per share to new investors at the assumed offering price.

• Stockholders' equity as of June 30, 2025, was $(1.9) million actual, projected to be $2.1 million as adjusted for the offering.

Use of proceeds and capital allocation

• Net proceeds intended for working capital and general corporate purposes, including advancing investigational biotherapeutic candidates and delivery partnering business.

• Proceeds expected to fund operations into the second quarter of 2026, with additional funding required thereafter.